Series on Cancer Therapy

Check out our Series of Review articles on emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical work to the clinic. 

Announcements

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

    • Glioblastoma multiforme (GBM) is a lethal form of primary brain cancer. A new study now implicates beta-secretase 1 (BACE1) as a crucial regulator of pro-tumoral IL-6–STAT3 signaling in GBM-associated macrophages. An effective BACE1 inhibitor, clinically developed for Alzheimer’s disease, may offer new hope for GBM treatment.

      • Amaia Martinez-Usatorre
      • Michele De Palma
      News & Views
    • The mechanisms regulating the progression of benign tumors to malignant carcinomas remain incompletely understood. A new study identifies the transcription factor NR2F2 as a specific regulator of this transition that plays critical roles in the maintenance of the malignant tumor state.

      • Hui Yi Grace Lim
      • Nick Barker
      News & Views
    • Acute myeloid leukemia (AML) is a heterogeneous disease with limited therapeutic options. A new study identifies leukocyte immunoglobulin-like receptor 3 (LILRB3) as a marker of monocytic AML, with the ability to modulate NF-κB signaling and to promote survival and immune evasion. Blockade of LILRB3 signaling could provide a novel therapeutic strategy in monocytic AML.

      • Audrey Lasry
      • Iannis Aifantis
      News & Views
    • Shedding light on epigenetic mechanisms controlling anti-tumor immune responses, a new study shows that the tumor-intrinsic ring finger protein 2 (RNF2), the catalytic subunit of Polycomb repressor complex 1 (PRC1), acts as a negative regulator of a collaborative NK and CD4+ T cell anti-tumor immune response against breast cancer.

      • Janneke G. C. Peeters
      • Michel DuPage
      News & Views
    • Clinical interpretation of cancer genomes for therapy selection and clinical hypothesis generation is an urgent and complex endeavor. A new study brings together a diverse set of data sources to automatically prioritize first- and second-order genomic alterations to provide a meaningful set of interpretations based on a patient’s molecular profile.

      • Ahmet Zehir
      • Michael F. Berger
      News & Views
  • Nature Cancer editors are always available to interact with researchers, be they authors, referees or readers.

    Editorial
  • Peer review is a cornerstone of the scientific publication process. High-quality refereeing is its essential element.

    Editorial
  • What happens to a manuscript after submission? How does the editor reach a decision? What is the editor’s role during peer review? We take a look into the editorial process at Nature Cancer.

    Editorial
  • The Biden administration has proposed a new agency to drive innovation in health research, including cancer. The focus on cancer and accelerated development is welcome, but for the time being, whether and how these plans will materialize is less clear.

    Editorial
  • Social media have emerged as a key communication tool for scientists. Here we explore how to reap the benefits and avoid the pitfalls of social networking.

    Editorial
Clinical Cancer Genomics

Clinical Cancer Genomics

Advances in sequencing and genomic technologies are rapidly expanding our understanding of cancer and in turn the role of genomics in clinical oncology.
Series